Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Virginia Commonwealth University Department of Education |
---|---|
Information provided by: | Virginia Commonwealth University |
ClinicalTrials.gov Identifier: | NCT00205491 |
The purpose of this study is to determine if treatment with venlafaxine reduces symptoms of depression in persons with traumatic brain injury.
Condition | Intervention | Phase |
---|---|---|
TBI (Traumatic Brain Injury) |
Drug: Venlafaxine |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Efficacy Study |
Official Title: | Pharmacological Intervention in Depression After Traumatic Brain Injury (A Research Study Within the Traumatic Brain Injury Model System) |
Estimated Enrollment: | 100 |
Study Start Date: | October 2004 |
Study Completion Date: | September 2007 |
The study evaluates the benefits of a promising antidepressant medication for the treatment of persons with traumatic brain injury (TBI) and major depressive disorder (MDD). The study is a randomized, double-blind, placebo-controlled trial of venlafaxine (a serotonin and norepinephrine reuptake inhibitor, also known as Effexor). Venlafaxine has been well established in the treatment of MDD in healthy individuals and is a recommended depression treatment agent for persons with TBI. By using a rigorous scientific methodology, this study will be an important first step in advancing the treatment of depression in this population beyond general impressions to proven treatments.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Virginia | |
Virginia Commonwealth University | |
Richmond, Virginia, United States, 23298 |
Principal Investigator: | Jeffrey S. Kreutzer, PhD | Virginia Commonwealth University |
Study ID Numbers: | H133A02051602, H133A020516 |
Study First Received: | September 12, 2005 |
Last Updated: | October 23, 2007 |
ClinicalTrials.gov Identifier: | NCT00205491 |
Health Authority: | United States: Food and Drug Administration |
depression after brain injury traumatic brain injury Venlafaxine |
Craniocerebral Trauma Depression Wounds and Injuries Central Nervous System Diseases Disorders of Environmental Origin Trauma, Nervous System Depressive Disorder |
Brain Diseases Serotonin Behavioral Symptoms Mental Disorders Venlafaxine Mood Disorders Brain Injuries |
Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Psychotropic Drugs Serotonin Uptake Inhibitors |
Pharmacologic Actions Serotonin Agents Therapeutic Uses Antidepressive Agents, Second-Generation Central Nervous System Agents Antidepressive Agents |